These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38518434)

  • 1. Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam.
    Schoemaker R; Krauwinkel W; Elshoff JP; Stockis A
    Epilepsy Res; 2024 May; 202():107332. PubMed ID: 38518434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.
    Schoemaker R; Wade JR; Stockis A
    Clin Pharmacokinet; 2018 Jul; 57(7):843-854. PubMed ID: 28884437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open-label, single-arm study.
    Pressler R; Boylan G; Dempsey E; Klotz KA; Krauwinkel W; Will E; Morita D; Floricel F; Elshoff JP; van den Anker J
    Epilepsia Open; 2024 Apr; 9(2):522-533. PubMed ID: 38049197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive brivaracetam - A prospective audit of outcomes from an epilepsy clinic.
    Stephen L; Brodie MJ
    Epilepsy Behav; 2021 Mar; 116():107746. PubMed ID: 33517200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
    Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S
    Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.
    Klein P; Bourikas D
    Adv Ther; 2024 Jul; 41(7):2682-2699. PubMed ID: 38811492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.
    Schoemaker R; Wade JR; Stockis A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):727-733. PubMed ID: 28280887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy.
    Kim MJ; Yum MS; Yeh HR; Ko TS; Lim HS
    J Clin Pharmacol; 2018 Dec; 58(12):1586-1596. PubMed ID: 30052270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
    Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
    Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
    Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
    Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up.
    Strzelczyk A; Zaveta C; von Podewils F; Möddel G; Langenbruch L; Kovac S; Mann C; Willems LM; Schulz J; Fiedler B; Kurlemann G; Schubert-Bast S; Rosenow F; Beuchat I
    Epilepsia; 2021 Dec; 62(12):2994-3004. PubMed ID: 34608628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials.
    Patel AD; Badalamenti V; Gasalla T; Elmoufti S; Elshoff JP
    Eur J Paediatr Neurol; 2020 Mar; 25():68-76. PubMed ID: 31810577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
    Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
    Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.
    Maglalang PD; Sinha J; Zimmerman K; McCann S; Edginton A; Hornik CP; Hornik CD; Muller WJ; Al-Uzri A; Meyer M; Chen JY; Anand R; Perrin EM; Gonzalez D;
    Clin Pharmacokinet; 2024 Jun; 63(6):885-899. PubMed ID: 38814425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of brivaracetam in pediatric epilepsy.
    Verrotti A; Grasso EA; Cacciatore M; Matricardi S; Striano P
    Acta Neurol Scand; 2021 Jan; 143(1):19-26. PubMed ID: 32966640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial.
    Lagae L; Klotz KA; Fogarasi A; Floricel F; Reichel C; Elshoff JP; Fleyshman S; Kang H
    Epilepsia; 2023 Nov; 64(11):2934-2946. PubMed ID: 37597326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.